Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...

SÖDERTÄLJE, Sweden I March 17, 2025 I Anocca AB, a leading T-cell immunotherapy company, announces the authorisation of its Clinical Trial Application (CTA) ...

CAMBRIDGE, UK I March 17, 2025 I Maxion Therapeutics (”Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G ...

I Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1bn, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, and ...

HONG KONG, China I March 16, 2025 I Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been ...

LONDON, UK I March 17, 2025 I AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising ...

NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...

GAINESVILLE, FL, USA I March 14, 2025 I iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, ...

BRIDGEWATER, NJ, USA I March 14, 2025 I Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug ...

SAN FRANCISCO, CA, USA and SUZHOU, China I March 14, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...